ArcticZymes Technologies — Investor Presentation 2016

Feb 3, 2016

OSE-filing

Biotec Pharmacon: Invitation to Q4 2015 presentation and Capital Markets Day

(Tromsø, 3 February 2016) Biotec Pharmacon ASA ("Biotec"), OSE: BIOTEC) will host a Capital Markets Day (CMD) Thursday 11 February 2016, following the Q4 presentation.

Time: 08:30 – 11:00

Location: Hotel Continental, Stortingsgaten 24/26, 0117 Oslo

Breakfast will be served prior to the presentations. For practical reasons, investors, analysts and journalists are encouraged to register via email to ir@biotec.no by 8 February 2016.

Capital Markets Day agenda

0830 – 0900 Q4 Presentation, Svein Lien, CEO 0905 – 0905 CMD Introduction, Svein Lien, CEO 0905 – 0925 SBG Scientific platform, Rolf Engstad, CSO 0925 – 1000 Woulgan, Stuart Devine, Marketing Director 1000 – 1015 Q&A 1015 – 1045 ArcticZymes, Jethro Holter, Managing Director 1045 – 1050 Closing remarks and outlook, Svein Lien, CEO 1050 – 1100 Q&A

The presentation material from Biotec's Capital Markets Day will be made available from 08:00 through newsweb.no and www.biotec.no. The presentations will be webcasted live and in replay on www.biotec.no. It will be possible to post questions through webcast console.

For additional information, please contact:

Børge Sørvoll, CFO +47 95 29 01 87 borge.sorvoll@biotec.no

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel immunomodulating products, including Woulgan®, a premium priced product in the advanced wound care market. ArcticZymes develops, produces and markets enzymes of marine origin used in molecular DNA technologies and diagnostics, representing growth markets where rapid technological developments are creating a strong demand for new and improved enzymes.